Terns Pharmaceuticals recently presented positive Phase 1 trial results for TERN-701, its investigational chronic myeloid leukemia therapy, showing a 75% major molecular response rate with favorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback